solid lipid microparticles of salbutamol sulfate for dry powder inhalation

Evaluation of flow properties of dry powder inhalation of salbutamol sulfate with lactose carrier.

The effects of the flow and packing properties of a drug/carrier powder mixture on emission of drug adhering to the carrier from capsules and inhalation devices were investigated. Model powder mixtures were designed consisting of lactose carriers with different particle shapes were prepared by surface treatment and micronized salbutamol sulfate. These powder mixtures were aerosolized by a Spinh...

Particulate Interactions in Dry Powder Formulations for Inhalation Particulate Interactions in Dry Powder Formulations for Inhalation

Inhalation powder and oral salbutamol combination.

Fifty six children with chronic asthma were treated with the inhaled dry powder of salbutamol or the combination of inhaled and oral salbutamol. Over three months the combination provided a significantly greater sustained symptomatic relief from asthma. Side effects were minimal and did not result in any withdrawals from the study.

An aerosol formulation of R-salbutamol sulfate for pulmonary inhalation.

An aerosol formulation containing 7.5 mg of R-salbutamol sulfate was developed. The aerosol was nebulized with an air-jet nebulizer, and further assessed according to the new European Medicines Agency (EMA) guidelines. A breath simulator was used for studies of delivery rate and total amount of the active ingredient at volume of 3 mL. A next generation impactor (NGI) with a cooler was used for ...

Dry powder inhalation: past, present and future.

INTRODUCTION Early dry powder inhalers (DPIs) were designed for low drug doses in asthma and COPD therapy. Nearly all concepts contained carrier-based formulations and lacked efficient dispersion principles. Therefore, particle engineering and powder processing are increasingly applied to achieve acceptable lung deposition with these poorly designed inhalers. Areas covered: The consequences of ...

Dry powder nitroimidazopyran antibiotic PA-824 aerosol for inhalation.

We formulated PA-824, a nitroimidazopyran with promise for the treatment of tuberculosis, for efficient aerosol delivery to the lungs in a dry powder porous particle form. The objectives of this study were to prepare and characterize a particulate form of PA-824, assess the stability of this aerosol formulation under different environmental conditions, and determine the pharmacokinetic paramete...